Use of perlecan domain V in treating amyloidogenic disease

dc.creator	Bix, Gregory J.
dc.creator	Wright, Sarah
dc.creator	Griswold-prenner, Irene
dc.date.accessioned	2019-06-17T17:11:07Z
dc.date.available	2019-06-17T17:11:07Z
dc.date.issued	2016-06-07
dc.identifier.uri	http://hdl.handle.net/1969.1/177150
dc.description.abstract	The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of Aβ peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.	en
dc.language	eng
dc.publisher	United States. Patent and Trademark Office
dc.rights	Public Domain (No copyright - United States)	en
dc.rights.uri	http://rightsstatements.org/vocab/NoC-US/1.0/
dc.title	Use of perlecan domain V in treating amyloidogenic disease	en
dc.type	Utility patent	en
dc.format.digitalOrigin	reformatted digital	en
dc.description.country	US
dc.contributor.assignee	THE Texas A&M UNIVERSITY SYSTEM
dc.identifier.patentapplicationnumber	13/519949
dc.date.filed	2011-01-06
dc.publisher.digital	Texas A&M University. Libraries
dc.subject.cpcprimary	A61K 38/39